![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Active Filter(s):
Details:
Lupin has completed the acquisition of two well-known brands, Aarane (sodium cromoglicate) in Germany and Nalcrom (cromoglicic acid) in Canada and the Netherlands, from Sanofi.
Lead Product(s): Sodium Cromoglicate,Bronchodil
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Aarane
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Lupin Ltd
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition June 05, 2024